DE60311252D1 - Stellenspezifische listeria-integrationsvektoren und verfahren zu deren verwendung - Google Patents

Stellenspezifische listeria-integrationsvektoren und verfahren zu deren verwendung

Info

Publication number
DE60311252D1
DE60311252D1 DE60311252T DE60311252T DE60311252D1 DE 60311252 D1 DE60311252 D1 DE 60311252D1 DE 60311252 T DE60311252 T DE 60311252T DE 60311252 T DE60311252 T DE 60311252T DE 60311252 D1 DE60311252 D1 DE 60311252D1
Authority
DE
Germany
Prior art keywords
methods
bacteriophage
vectors
job
listeria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60311252T
Other languages
English (en)
Other versions
DE60311252T3 (de
DE60311252T2 (de
Inventor
Daniel A Portnoy
Richard Calendar
Peter M Lauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29249682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60311252(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of DE60311252D1 publication Critical patent/DE60311252D1/de
Application granted granted Critical
Publication of DE60311252T2 publication Critical patent/DE60311252T2/de
Publication of DE60311252T3 publication Critical patent/DE60311252T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60311252T 2002-04-30 2003-04-29 Stellenspezifische listeria-integrationsvektoren und verfahren zu deren verwendung Expired - Lifetime DE60311252T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US136860 2002-04-30
US10/136,860 US7425449B2 (en) 2002-04-30 2002-04-30 Site specific Listeria integration vectors and methods for using the same
EP03736520A EP1504095B2 (de) 2002-04-30 2003-04-29 Stellenspezifische listeria-integrationsvektoren und verfahren zu deren verwendung
PCT/US2003/013492 WO2003092600A2 (en) 2002-04-30 2003-04-29 Site specific listeria integration vectors and methods for using the same

Publications (3)

Publication Number Publication Date
DE60311252D1 true DE60311252D1 (de) 2007-03-08
DE60311252T2 DE60311252T2 (de) 2007-11-22
DE60311252T3 DE60311252T3 (de) 2011-06-30

Family

ID=29249682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60311252T Expired - Lifetime DE60311252T3 (de) 2002-04-30 2003-04-29 Stellenspezifische listeria-integrationsvektoren und verfahren zu deren verwendung

Country Status (9)

Country Link
US (6) US7425449B2 (de)
EP (1) EP1504095B2 (de)
JP (1) JP2005523716A (de)
AT (1) ATE351913T1 (de)
AU (1) AU2003237138B2 (de)
CA (1) CA2484185A1 (de)
DE (1) DE60311252T3 (de)
ES (1) ES2280758T5 (de)
WO (1) WO2003092600A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
EP1513924A4 (de) * 2002-05-29 2008-05-21 Univ California Attenuierte listeria spp. und verfahren zur verwendung davon
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4839209B2 (ja) * 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
JP2007509067A (ja) * 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
JP5530065B2 (ja) 2004-08-13 2014-06-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
US20060121053A1 (en) * 2004-10-18 2006-06-08 Pamela Sweeney High cell density process for growth of Listeria
EP1957100B1 (de) 2005-11-29 2016-07-13 Intrexon Actobiotics NV Induktion von schleimhauttoleranz gegen antigene
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
EP2860253B1 (de) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Manipulierte Listerien und Anwendungsverfahren dafür
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
EP2125010B1 (de) 2007-01-25 2014-06-04 Actogenix N.V. Behandlung von immunkrankheiten durch mukosale abgabe von antigenen mit genetisch modifiziertem lactobacillus
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
EP2403935B1 (de) 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Zusammensetzungen mit angiogenen faktoren und verwendungsverfahren dafür
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
JP2015511602A (ja) 2012-03-12 2015-04-20 アドバクシス， インコーポレイテッド リステリアワクチン処理後のサプレッサー細胞機能抑制
JP2015534822A (ja) * 2012-11-06 2015-12-07 アデュロ バイオテック，インコーポレイテッド 条件的弱毒化細菌種ならびにその調製法および使用法
NO339948B1 (no) * 2013-12-20 2017-02-20 Energynest As Element for termisk energilager
FR3016633B1 (fr) 2014-01-17 2018-04-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Immunoglobuline anti-toxine du charbon
US9976149B2 (en) 2014-05-08 2018-05-22 Ramot At Tel-Aviv University Ltd. Modified listeria bacteria and uses thereof
WO2016073585A1 (en) 2014-11-05 2016-05-12 The Regents Of The University Of California General secretory pathway (gsp) mutant listeria spp., and methods for making and using the same
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
EP0934421A1 (de) * 1997-08-06 1999-08-11 Laboratorio Medinfar-Produtos Farmaceuticos LDA. Dna-integrierung in das genom von mycobakterium spp. durch trans-komplementierung mit hilfe eines zielortgerichteten integrationssystems
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
AU2001242019A1 (en) 2000-07-06 2002-02-05 Xenogen Corporation Compositions and methods for use thereof in modifying the genomes of microorganisms
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same

Also Published As

Publication number Publication date
US20170204423A1 (en) 2017-07-20
EP1504095B1 (de) 2007-01-17
US20110027319A1 (en) 2011-02-03
US7749510B2 (en) 2010-07-06
WO2003092600A2 (en) 2003-11-13
EP1504095A4 (de) 2005-06-22
AU2003237138A1 (en) 2003-11-17
WO2003092600A3 (en) 2004-04-08
US20070059322A1 (en) 2007-03-15
EP1504095A2 (de) 2005-02-09
US20150037369A1 (en) 2015-02-05
AU2003237138B2 (en) 2008-04-03
ES2280758T5 (es) 2011-05-04
US9556441B2 (en) 2017-01-31
EP1504095B2 (de) 2010-12-29
ATE351913T1 (de) 2007-02-15
US7425449B2 (en) 2008-09-16
JP2005523716A (ja) 2005-08-11
CA2484185A1 (en) 2003-11-13
US8865469B2 (en) 2014-10-21
US20120321662A1 (en) 2012-12-20
US20030203472A1 (en) 2003-10-30
DE60311252T3 (de) 2011-06-30
US8192991B2 (en) 2012-06-05
ES2280758T3 (es) 2007-09-16
DE60311252T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
DE60311252D1 (de) Stellenspezifische listeria-integrationsvektoren und verfahren zu deren verwendung
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
ATE518956T1 (de) Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
CY1109708T1 (el) Αντιγονα του neisseria meningitidis
HUP0302376A2 (hu) Anti-TNF ellenanyagok, készítmények, eljárások és alkalmazások
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE69824013D1 (de) Impfstoff gegen hpv
DE60310562D1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE309196T1 (de) Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
ATE318899T1 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
DE69932832D1 (de) Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE69322092D1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
IL164178A (en) Fusion protein comprising at least four hiv proteins and vaccine comprising said fusion protein
ATE254474T1 (de) Impfstoffzusammensetzung gegen herpes simplex virus und methoden zur verwendung
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
DE60042816D1 (de) T-helferzellen-epitope
EA200600738A1 (ru) Способ

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings